Teprotumumab – March 2025

• Brand names:
  • Tepezza®
• Pharmaceutical Company:
  • AMGEN AUSTRALIA PTY LTD
• Condition/Indication: Thyroid eye disease
• Meeting Date: March 2025
• Public Summary Document (PSD) March 2025 May 2025 PBAC Meetings - (PDF 1.6MB)
• Public Summary Document (PSD) March 2025 May 2025 PBAC Meetings - (Word 825KB)

Related Public Summary Documents

• Teprotumumab – May 2025